Virus Vectors Expressing Multiple Epitopes of Tumor Associated Antigens For Inducing Antitumor Immunity
US-2018000912-A1 · Jan 4, 2018 · US
Methods and compositions for treating cancer
US11419928B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11419928-B2 |
| Application number | US-201816170534-A |
| Country | US |
| Kind code | B2 |
| Filing date | Oct 25, 2018 |
| Priority date | Oct 25, 2017 |
| Publication date | Aug 23, 2022 |
| Grant date | Aug 23, 2022 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Provided herein, in some embodiments, are methods and composition for treating cancer in a subject. The methods may include administering to the subject a nucleic acid encoding MIP3α fused to a cancer antigen, administering to the subject a CpG oligodeoxynucleotide, administering to the subject interferon alpha (IFNα), and administering to the subject 5-aza-2′-deoxycytidine (Aza), in effective amounts to treat the cancer.
First claim
Opening claim text (preview).
What is claimed is: 1. An engineered nucleic acid comprising the sequence of SEQ ID NO: 19 or encoding the sequence of SEQ ID NO: 20.
Assignees
Inventors
Classifications
Antineoplastic agents · CPC title
Proteins · CPC title
Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose · CPC title
the peptide or protein in the drug conjugate being a receptor, e.g. CD4, a cell surface antigen, i.e. not a peptide ligand targeting the antigen, or a cell surface determinant, i.e. a part of the surface of a cell · CPC title
Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US11419928B2 cover?
- Provided herein, in some embodiments, are methods and composition for treating cancer in a subject. The methods may include administering to the subject a nucleic acid encoding MIP3α fused to a cancer antigen, administering to the subject a CpG oligodeoxynucleotide, administering to the subject interferon alpha (IFNα), and administering to the subject 5-aza-2′-deoxycytidine (Aza), in effective …
- Who is the assignee on this patent?
- Univ Johns Hopkins
- What technology area does this patent fall under?
- Primary CPC classification A61K39/00119. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Aug 23 2022 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).